Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis

Basit Öğe Kaydı
dc.contributor.authorAltintas, Abdullah
dc.contributor.authorKarahan, Zulkuf
dc.contributor.authorPasa, Semir
dc.contributor.authorCil, Timucin
dc.contributor.authorBoyraz, Taylan
dc.contributor.authorIltumur, Kenan
dc.contributor.authorAyyildiz, Orhan
dc.date.accessioned2024-04-24T16:24:53Z
dc.date.available2024-04-24T16:24:53Z
dc.date.issued2007
dc.departmentDicle Üniversitesien_US
dc.description.abstractIncreased incidence of pulmonary hypertension ( PH) has been reported in patients with chronic myeloproliferative disorders. The exact incidence of PH in essential thrombocythemia ( ET) is unknown. Most of the reported literature consists of case reports or small studies. We designed this study to asses the incidence of PH in patients with ET and reactive thrombocytosis. Previously or newly diagnosed 46 patients with ET, and 40 patients with reactive thrombocytosis secondary to iron deficiency anemia were found to be eligible for this study. Diagnosis of PH was established via transthoracic echocardiography. PH was found in 22 ( 47.8%) out of 46 patients with ET. Seven patients with PH were newly diagnosed ET, 5 patients with PH were in low, and the other patients with PH were in intermediate or high risk category. We found statistically significant difference in terms of platelet counts between ET patients with PH and without PH ( p = 0.027). None of the patients with reactive thrombocytosis had PH. In conclusion, PH appears to be common in patients with ET. Therefore, all patients with ET should be evaluated for PH. Larger and prospective studies are required to clarify the long-term impact of PH on the survival of these patients. Future studies are also needed to determine whether cytoreductive treatment and aspirin prevent the development of PH, and to determine the effects of cytoreductive treatments and aspirin on the prognosis of PH. The effect of PH on ET prognosis should also be determined in low risk ET patients.en_US
dc.identifier.doi10.1080/10428190701493928
dc.identifier.endpage1987en_US
dc.identifier.issn1042-8194
dc.identifier.issn1029-2403
dc.identifier.issue10en_US
dc.identifier.pmid17852711
dc.identifier.scopus2-s2.0-35148883400
dc.identifier.scopusqualityQ2
dc.identifier.startpage1981en_US
dc.identifier.urihttps://doi.org/10.1080/10428190701493928
dc.identifier.urihttps://hdl.handle.net/11468/16888
dc.identifier.volume48en_US
dc.identifier.wosWOS:000249872600016
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofLeukemia & Lymphoma
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEssential Thrombocythemiaen_US
dc.subjectPulmonary Hypertensionen_US
dc.subjectEchocardiographyen_US
dc.subjectThrombocytosisen_US
dc.titlePulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosisen_US
dc.titlePulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu